Praveen Keshava, MD
Ophthalmology · Rutland, VTNPI 1336165596
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Rxsight Inc accounts for 77.4% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $246 and has fallen 86.8% since, to $32 in 2025.
Across 4 payments — averaging $89.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$278
- Surgical Specialties Corporation (US), Inc. (dba Corza Medical)$67
- Sight Sciences, Inc.$14
What the payments were for
- Speaking & faculty fees$329%
- Food & beverage$32791%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 2 | $278 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 1 | $67 |
| Sight Sciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$360 in reported general payments places this provider in the 80th percentile of 35 ophthalmology providers in Vermont.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 47 | $63,385 |
| Cyclosporine | 64 | $39,292 |
| LumiganBimatoprost | 92 | $39,020 |
| Brimonidine Tartrate | 139 | $8,766 |
| Latanoprost | 891 | $8,646 |
| Travoprost | 33 | $6,781 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 37 | $5,800 |
| Timolol Maleate | 223 | $5,227 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 282 | $5,006 |
| Fluorometholone | 63 | $4,308 |
| Prednisolone Acetate | 86 | $3,902 |
| Loteprednol Etabonate | 32 | $3,336 |
| Alphagan PBrimonidine Tartrate | 12 | $3,131 |
| Ketorolac Tromethamine | 48 | $2,469 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $2,205 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Rutland
- John CocoRutland$21
- Vered SobelRutland$0
- Christopher ConnorWindsor$187K
- Shaunak BakshiSouth Burlington$4K
- John HinkleSouth Burlington$4K
- Jonathan ManhardSouth Burlington$2K
- Stephen PhippsSt Johnsbury$1K
- Jillian KaplitaMiddlebury$1K
- Chantal BoisvertBurlington$324
- Miranda RenfrowSaint Johnsbury$313
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.